×
About 1,088 results

ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Research & Reviews  334 results

Plasmacytic Pleural Effusion as a Major Presentation of Angioimmunoblastic T-Cell Lymph...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600574
Current Oncology (Toronto, Ont.); Li B, Nong L et. al.

Oct 28th, 2022 - Angioimmunoblastic T-cell lymphoma is one of the peripheral T-cell lymphomas. Reactive plasma cells can occasionally be observed in AITL patients' peripheral blood and bone marrow. Plasmacytic pleural effusion as the presentation of AITL has not b...

Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma:...
https://doi.org/10.1002/mc.23476
Molecular Carcinogenesis; Hou Y, Zi J et. al.

Oct 28th, 2022 - Liquid biopsy has been experimented with to identify the mutation of lymphoma based on next-generation sequencing (NGS). We applied NGS analysis to circulating tumor DNA (ctDNA) in 20 lymphoma patients. Then, we compared treatment outcomes, and cl...

Angioimmunoblastic T-cell lymphoma with elevated serum IgA and infiltration of IgA-posi...
https://doi.org/10.5070/D328458523
Dermatology Online Journal; Tabata N, Kunikata N et. al.

Oct 20th, 2022 - Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common types of peripheral T-cell lymphoma. Laboratory examination exhibits immunological abnormalities, such as polyclonal hypergammaglobulinemia and hemolytic anemia. Skin lesions are ...

Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell ly...
https://doi.org/10.1016/j.ejca.2022.09.008
European Journal of Cancer (Oxford, England : 1990); Meeuwes FO, Brink M et. al.

Oct 9th, 2022 - Patients with angioimmunoblastic T-cell lymphoma (AITL) are treated with cyclophosphamide, doxorubicin, vincristine and prednisone with or without etoposide (CHO(E)P). In the majority of cases, Epstein-Barr virus (EBV)-positive B-cells are present...

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-c...
https://doi.org/10.3324/haematol.2022.280996
Haematologica Rai S, Kim WS et. al.

Oct 7th, 2022 - Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of histone deacetylase (HDAC) inhibitor that selectively blocks class I and class IIb HDACs. This multicenter phase IIb study aimed to investigate the efficac...

see more →

Guidelines  1 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  28 results

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
https://clinicaltrials.gov/ct2/show/NCT04858256

Oct 7th, 2022 - Patients will receive single-agent treatment with pacritinib 200mg orally twice daily until any condition for treatment discontinuation has been met. Patients will be enrolled into one of four cohorts: Peripheral T-Cell Lymphoma, not otherwise spe...

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT03905135

Sep 13th, 2022 - Background: Mature T-cell cancers are a phenotypically heterogeneous group of malignancies which constitute 10-15% of all non-Hodgkin lymphomas (NHL). Patients with relapsed/refractory T cell lymphomas have limited therapeutic options, making new ...

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL
https://clinicaltrials.gov/ct2/show/NCT03593018

Aug 25th, 2022 - Compared to B-cell Non-Hodgin Lymphoma (NHL), Angioimmunoblastic T-cell Lymphoma (AITL) is more resistant to conventional chemotherapy and is generally associated with an inferior outcome. In case of relapsed of refractory disease, survival durati...

Study of Lacutamab in Peripheral T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04984837

Aug 19th, 2022 - This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lympho...

Transplantation After Complete Response In Patients With T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05444712

Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...

see more →

News  71 results

FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL
https://www.onclive.com/view/fda-grants-fast-track-designation-to-mt-101-for-cd5-relapsed-refractory-ptcl

Nov 21st, 2022 - The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma (PTCL), according to an announcement from Myeloid Therapeutics, Inc.1...

European Commission Grants Orphan Drug Designation to Nana-val for Peripheral T-cell Lymphoma
https://www.onclive.com/view/european-commission-grants-orphan-drug-designation-to-nana-val-for-peripheral-t-cell-lymphoma

Sep 27th, 2022 - The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir (Nana-val) for use as a potential therapeutic option in patients with peripheral T-cell lymphoma (PTCL), according to an announcement from Viracta Th...

Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL
https://www.onclive.com/view/tolinapant-displays-encouraging-activity-and-safety-in-relapsed-refractory-ptcl-ctcl

Aug 31st, 2022 - Single-agent tolinapant (ASTX660) generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), according to data from the phase 2 A...

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL
https://www.onclive.com/view/dr-mehta-shah-on-the-variations-of-the-chop-regimen-in-ptcl

Jul 20th, 2022 - Neha Mehta-Shah, MD, MSCI, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, and medical oncologist, Siteman Cancer Center, discusses variations of CHOP-based c...

CHOP-Based Combinations Represent Evolving Standard of Care in Frontline Treatment of PTCL
https://www.onclive.com/view/chop-based-combinations-represent-evolving-standard-of-care-in-frontline-treatment-of-ptcl

Jul 19th, 2022 - CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard of care in the frontline setting for patients with peripheral T-cell lymphoma (PTCL). Although the addition of agents including etoposide and...

see more →